The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.
Fracture is one of the important complications in female. Osteoporosis should be treated in postmenopausal female due to high risk of fracture. Recently, there have been many classes of medications developed for preventing bone loss. Raloxifene, an oral form of anti-osteoporosis medication, has been reported to improved central nervous disorders. Therefore, this study is designed to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
500
Raloxifene tratment more than 4 weeks
Alendronic acid 70mg with Colecalciferol 70mcg
outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital
Taichung, Taiwan
RECRUITINGTaichung Veterans General Hospital
Taichung, Taiwan
RECRUITINGBrain-derived neurotrophic factor
Serum brain-derived neurotrophic factor (BDNF) Levels
Time frame: 3 months
Brain-derived neurotrophic factor
Serum brain-derived neurotrophic factor (BDNF) Levels
Time frame: 1 year
Vascular cell adhesion molecule-1
Serum vascular cell adhesion molecule-1 (VCAM-1) levels
Time frame: 3 months
Orexin-A
Serum Orexin-A levels
Time frame: 3 months
Body components
Fat tissue ratio
Time frame: 3 months
Zung self-rating depression scale
Questionnaire for depressive symptoms
Time frame: 3 months
5-Item Geriatric Depression Scale
Questionnaire for Cognitive assessment
Time frame: 3 months
The Mini Mental State Examination (MMSE)
Questionnaire for Cognitive assessment
Time frame: 3 months
The Barthel index
Questionnaire for Cognitive assessment
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Instrumental Activities of Daily Living (IADL)
Questionnaire for Cognitive assessment
Time frame: 3 months
ankle-brachial index
Peripheral artery disease assessment
Time frame: 3 months